



PCT/GB 2003 / 0 0 5 4 0 3



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

RECEIVED

22 JAN 2004

WIPO

PCT

PRIORITY DOCUMENT


SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



R. Mahoney

Signed

Dated 13 January 2004

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
(Rule 16)

THE PATENT OFFICE

A

11 DEC 2002

RECEIVED BY FAX

The
Patent
Office11DEC02 E770265-1 D02973
P01/7700 0.00-0228900.7**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP9 1RH

1. Your reference

P101004GB

2. Patent application number

(The Patent Office will fill in this part)

0228900.7

11 DEC 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

M L Laboratories Plc
17 Hanover Square
LONDON
W1S 1HU

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

GB

08325578001

4. Title of the invention

Cancer Immunotherapy

5. Name of your agent (if you have one)

Harrison Goddard Foote

"Address for service" in the United Kingdom Orlando House
to which all correspondence should be sent 11c Cornpstall Road
(including the postcode) Marple BridgeStockport SK6 6HH
United Kingdom

Patents ADP number (if you know it)

14571002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d).)

Yes

Patents Form 1/77

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 18

Claim(s) 2

Abstract 1

Drawing(s) 6 only

CF

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 8/77) 1 /

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify) 1

Covering letter /

11.

I/We request the grant of a patent on the basis of this application.

Signature

Harrison Goddard Foote

Date

Harrison Goddard Foote

11 December 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

David Garnett

0161 427 7005

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Patents Form 1/77

11/Dec/2002

1

Cancer immunotherapy

DUPLICATE

Field of the invention

This invention is in the field of the treatment of cancers. More specifically it is in the field of tumour-associated antigens, and the generation of anti-tumour immune responses.

Background of the invention

Tumours arise due to the improper regulation of gene transcription resulting in aberrant cell growth and proliferation. This improper gene regulation results in abnormal expression of genes. Some of these genes code for tumour-associated antigens. Tumour associated antigens are proteins that are abnormally expressed in tumours, either being expressed when they are not normally, or being expressed at a level significantly higher than normal. A tumour-associated antigen is specifically a protein expressed in tumour cells that either elicits or is capable of eliciting an immune response in the tumour-bearing host.

Specific cytotoxic T cell responses against tumour associated antigens have been detected in patients and been shown to be responsible for spontaneous regressions. Many tumour-associated antigens have been identified. Tumour-associated antigens have been considered to fall into one of three main categories. The cancer/testis antigens are those that are expressed in cancers and testis. Examples of these are the MAGE family of melanoma antigens. The differentiation antigens are antigens that are normally expressed at low levels but are significantly upregulated in cancers. The differentiation antigens are associated with melanoma and examples are MART-1/MelanA and gp100. The third type of antigens are the mutated antigens, antigens that are mutated versions of genes normally expressed. Tumour-associated antigens play an important role in the field of cancer immunotherapy.

Polycomb-group proteins play a pivotal role in development, haematopoiesis and cell cycle regulation. They form large multimeric complexes which are thought to bind to approximately 100 chromosomal sites (in *Drosophila*) and are involved in transcriptional repression. There have been 2 polycomb protein complexes described to date. One contains Enx/EZH2, EED, HDAC1/2 histone deacetylases and YY1, the other contains BMI-1, RING-1, HPH1, HPH2, HPC1, HPC2, HPC3 and CtBP (see Raaphorst *et al.* (2001) 166:5925-5934 for references). These complexes have been suggested to have opposing activities and they influence the proliferative state of cells (Raaphorst *et al.* (2001) 166:5925-5934). It has also been proposed

that these two complexes, although both are involved in transcriptional repression, play different roles with one initiating the repression of target genes while the other maintains the repression (van Lohuizen, *Curr. Opin. Genet. Dev.* (1999) 9:355-361).

BMI-1 was originally discovered through studies of retroviral insertional mutagenesis in Eμ-*myc* transgenic mice. These mice were noted to have a significantly reduced latency period for the development of pre-B-cell lymphomas. Analysis of the sites of retroviral insertion revealed that insertion near *bmi-1* was common and resulted in *bmi-1* overexpression (Haupt, Y. *et al.* *Cell* (1991) 65:753-763). Consistent with this, crossing of Eμ-*bmi-1* mice with Eμ-*myc* mice results in the accelerated onset of both T and B cell lymphomas (Haupt Y. *et al.* *Oncogene* (1993) 8:3161-3164). Thus *bmi-1* is an oncogene initially described as being associated with lymphomas. BMI-1 is a polycomb group protein. BMI-1 expression tends to decrease during cell differentiation, thus highest levels are present in purified CD34+ progenitor/stem cells and there is essentially no expression in mature B and T cells (Lessard *et al.* *Blood* (1998) 91:1216-1224). Human studies have suggested that BMI-1 has a role in both B and T cell differentiation (Raaphorst *et al.* *Am. J. Pathol.* (2000) 157:709-715; Raaphorst *et al.* *J. Immunol.* (2001) 166:5925-5934). Thus, it follows that aberrant expression of *bmi-1* could result in tumour formation.

BMI-1 associates with chromatin in a cell-cycle dependent manner (Voncken *et al.* *J. Cell Sci.* (1999) 112:4627-4639).

Bmi-1 misregulation has been associated with a number of cancer types including lymphomas (Beà *et al.* (2001) *Cancer Res.* 61:2409-2412; van Kemenade *et al.* (2001) *Blood* 97:3896-3901), non-small cell lung cancer (Voulantzen *et al.* *Br. J. Cancer* (2001) 84:1372-1376) and it has been postulated that it might be involved in breast cancer due to its over expression in a number of breast cancer cell lines and its transformation of mammary epithelial cells (Dimri *et al.* *Cancer Res.* (2002) 62:4736-4745). However, an analysis of *bmi-1* expression in a number of haematological malignancies, as well as solid tumours, concluded that *Bmi-1* overexpression is most common in mantle cell lymphomas and also that '*bmi-1* gene alterations in human neoplasms are uncommon' (Beà *et al.* 2001)

RING-1, another component of the same polycomb group protein complex as BMI-1, has also been shown to have oncogenic properties. Overexpression of RING-1 in a cell line resulted

11/Dec/2002

3

in cellular transformation as assessed by attachment independent growth and tumour formation in athymic mice (Satijn and Otte Mol. Cell Biol. (1999) 19:57-68).

Disregulation of another polycomb group protein, EZH2 (enhancer of zeste homolog 2), has also been associated with malignancy. Like BMI-1, EZH2 misregulation has been associated with haematological malignancies (van Kemenade *et al.* (2001) Blood 97:3896-3901). EZH2 has also been associated with non-haematopoietic malignancies. Increasing EZH2 levels in prostate cancer have been correlated both with disease stage and prognosis (Varambally *et al.* Nature (2002) 419:624-629).

International patent application WO 01/53834 (Otte / University of Amsterdam) describes methods of identifying and characterising tumour cells, by means of analysing their expression of proteins of the polycomb group complex and, in particular, BMI-1.

Thus the involvement of polycomb group proteins in tumorigenesis, especially in the haematopoietic system is well described in the prior art, however the use of these proteins as tumour-associated antigens has not been described. Due to the level of expression of these proteins in normal tissues those skilled in the art would presume that they are not good candidate tumour associated antigens. Also disclosed in the current application is the observation that *bmi-1* disregulation, particularly upregulation, is far more common than previously reported, and is detectable in a large range of non-haematological malignancies.

Summary of the invention

The present invention relates to the use of polycomb proteins as antigens for the immunotherapeutic treatment of cancer. Polycomb group proteins, especially BMI-1 and EZH2, have been shown to be aberrantly expressed in a number of cancers. However these proteins are also expressed in many normal tissues.

We demonstrate in the examples below that both humoral and cellular immune responses to polycomb proteins can be detected in the sera and peripheral blood mononuclear cell preparations from both cancer patients and healthy donors. Thus self-immune responses to these antigens can be generated in humans and these responses, at least at the levels detected appear not to have any pathological consequences. We also demonstrate that in a murine model significant anti-polycomb protein responses can be induced by vaccination.

11/Dec/2002

4

Antibody and T cell responses can be detected and these responses can have anti-tumour cell activity.

We have also shown that the expression of at least one polycomb protein, BMI-1, is highly upregulated in a large number of human tumour types.

Immunisation against tumour-associated antigens can be achieved using a number of approaches. These approaches can include but are not limited to genetic immunisation, protein vaccination, peptide vaccination, cell-based vaccination (especially dendritic cell vaccination), vaccination with virus-like particles (VLPs).

Genetic vaccination has been used in numerous preclinical cancer immunotherapy studies and in cancer immunotherapy trials. Genetic vaccination involves vaccination by delivering the genes encoding the antigen to which an immune response is required into cells of an individual (Ulmer *et al.* *Curr. Opin. Immunol.* (1996) 8:531-536). The genes can be delivered as plasmid DNA, either 'naked' or formulated to improve DNA transfection with lipids, etc., by simple intramuscular injection (Ulmer *et al.* *Science* 1993 259:1745-1748), by intradermal injection (Raz *et al.* *Proc. Natl. Acad. Sci.* 1994 91:9519-9523), by intranasal administration (Klavinskis *et al.* *J. Immunol.* 1999 162:254-262; Sasaki *et al.* *J. Virol.* 1998 72:4931-4939), or by topical application (Fan *et al.* *Nature Biotech* 1999 17:870-872). Alternatively the genes can be delivered as plasmid DNA coated onto high density (usually gold) beads that are 'fired' into the skin of an individual using a gene gun (Fynan *et al.* *Proc. Nat. Acad. Sci.* 1993 90:11478-11482; Fuller *et al.* *J. Med. Primatol.* 1996 25:236-241), as plasmid DNA in microparticles (Chen *et al.* *J. Virology* 1998: 5757-5761), as a eukaryotic expression construct in a bacterial delivery system (Sizemore *et al.*, 1995, *Science* 270: 299-302; Paglia *et al.*, 1998, *Blood* 92: 3172-3176) or in a recombinant virus, the virus being directly administered into an individual. Recombinant viruses used for genetic immunisation include, but are not limited to, adenovirus (Fooks *et al.* *Virology* 1995 210:456-465; Imler J-L. *Vaccine* 1995 13:1143-1151; Chen *et al.* *J. Immunol* 1996 156:224-231; Rosenberg *et al.* *J. Natl. Cancer Inst.* 1998 90:1894-1900), and pox viruses such as vaccinia virus (Epstein *et al.* *J. Immunol.* 1993 150:5484-5493; Graham *et al.* *J. Infect. Dis.* 1992 166:244-252).

Responses to genetic immunisation procedures can be boosted by modification of the antigen. This modification can take the form of ubiquitination to improve antigen degradation and thus presentation (Rodriguez *et al.* *J. Virology* 1997 71:8497-8503; Fu *et al.* *Vaccine*

11/Dec/2002

5

1998 16:1711-1717) and targeting antigen to sites or cells key to immune induction (Boyle *et al.* Nature 1998 392:408-411; Deliyannis *et al.* Proc. Natl. Acad. Sci. 2000, 97: 6676-6680)

Protein vaccination usually involves the administration of recombinant protein antigen in combination with an adjuvant. Protein vaccines are usually administered by the intramuscular, subcutaneous or intradermal routes (Vaccine Design, the subunit and adjuvant approach, Eds: Powell and Newman, Plenum Press, New York, 1995, and references therein).

Peptide vaccination involves vaccination with peptide epitopes from antigens. These peptides are usually MHC or HLA Class I-binding peptides designed to elicit CD8+ve cytotoxic T cell responses, however they may also include Class II restricted peptides. Peptide vaccination has shown anti-tumour efficacy in preclinical tumour models (Schallert *et al.* Eur. J. Immunol. 2002 32:752-760; Takigawa *et al.* Ann. N. Y. Acad. Sci. 2001 941:139-146; Lo-Man *et al.* J. Immunol. 2001 166:2849-2854), and has been tested in anti-cancer clinical trials (Jäger *et al.* Int. J. Cancer 1996 66:162-169; Jäger *et al.* Int. J. Cancer 1996 67:54-62; Rosenberg *et al.* Nature Medicine 1998 4:321-326).

Since the recent development of protocols for the generation of large numbers of dendritic cells *in vitro/ex vivo*, immunotherapy with *ex vivo* manipulated dendritic cells has become a promising field for cancer treatment (reviewed in Fong & Engleman Ann. Rev. Immunol. 2000 18:245-273). Dendritic cells can be 'loaded' with defined tumour-associated antigen using methodologies including, but not limited to, protein pulsing (Hsu *et al.* Nature Medicine (1996) 2:52-58; Reichardt *et al.* Blood (1999) 93:2411-2419), peptide-pulsing (Tjoa *et al.* The Prostate (1997) 32:272-278; Morse *et al.* Clinical Cancer Research (1999) 5:1331-1338; Thurner *et al.* J. Exp. Med. (1999) 190:1669-1678; Mackensen *et al.* Int. J. Cancer (2000) 86:385-392), DNA transfecting (Irvine *et al.* Nat. Biotech. (2000) 18:1273-1278; Lohmann *et al.* Cancer Gene Therapy (2000) 7:605-614), virally transducing (Ishida *et al.* Clin. Exp. Immunol. (1999) 117:224-251; Kaplan *et al.* J. Immunol. (1999) 163:699-707; Yang *et al.* J. Immunol. (2000) 164:4204-4211), and RNA-pulsing (Boczkowski *et al.* Cancer Research (2000) 60:1028-1034; Heiser *et al.* J. Clin. Invest. (2002) 109:409-417).

Bmi-1 is a self-protein and thus in order to generate an immune response to it tolerance must be broken. Thus to boost the generation of anti-bmi-1 immune responses a number of approaches can be taken, these approaches are well known to those skilled in the art. These

11/Dec/2002

6

approaches include but are not limited to, inclusion of non-self helper epitopes in the immunogen (Dalum *et al.* Nat. Biotech 1999 17:666-669), fusion of the antigen to a strong foreign antigen (King *et al.* Nature Medicine 1998 4:1281-1286), or use of a xenogeneic version of the antigen (Naftzger *et al.* Proc. Natl. Acad. Sci. 1996 93:14809-14814). All of these approaches are applicable to most, if not all, of the immunisation methodologies described above.

Optimal cancer therapies may involve the combination of BMI-1 with other tumour-associated antigens, thus increasing the breadth and hopefully potency of the immune response and limiting the chance of immune escape by tumour-associated antigen downregulation.

Accordingly, the invention provides, in a first aspect, a polycomb protein, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide encoding said protein, peptide or epitope, for use as a medicament in the immunotherapy of cancer. Preferably, the protein is selected from the list consisting of Enx/EZH2, EED, BMI-1, RING-1, HPH1, HPH2, HPC3 and CtBP, more preferably it is Enx/EZH2 or BMI-1, most preferably it is BMI-1.

Preferably, the cancer to be treated is derived from a tissue or organ selected from the list consisting of: liver, lung, breast, stomach, cervix, prostate, bladder, pancreas, brain, colorectal or ovary, or is a melanoma, lymphoma or leukaemia.

In a second aspect, the invention provides a vector comprising a polynucleotide encoding such a protein, or immunogenic peptide or epitope derived therefrom.

The vector may be any vector capable of transferring DNA to a cell. Preferably, the vector is an integrating vector or alternatively a non-integrating vector.

Preferred integrating vectors include recombinant retroviral vectors. A recombinant retroviral vector will include DNA of at least a portion of a retroviral genome which portion is capable of infecting the target cells. The term "infection" is used to mean the process by which a virus transfers genetic material to its host or target cell. Preferably, the retrovirus used in the construction of a vector of the invention is also rendered replication-defective to remove the effect of viral replication on the target cells. In such cases, the replication-defective viral genome can be packaged by a helper virus in accordance with conventional techniques. Generally, any retrovirus meeting the above criteria of infectivity and capability of functional

11/Dec/2002

7

gene transfer can be employed in the practice of the invention. Lentiviral vectors are especially preferred.

Suitable retroviral vectors include but are not limited to pLJ, pZlp, pWe and pEM, well known to those of skill in the art. Suitable packaging virus lines for replication-defective retroviruses include, for example, Ψ Crip, Ψ Cre, Ψ 2 and Ψ Am.

Other vectors useful in the present invention include adenovirus, adeno-associated virus, SV40 virus, vaccinia virus, HSV and poxvirus vectors. A preferred vector is the adenovirus. Adenovirus vectors are well known to those skilled in the art and have been used to deliver genes to numerous cell types, including airway epithellum, skeletal muscle, liver, brain and skin (Hitt, MM, Addison CL and Graham, FL (1997) *Advances in Pharmacology* **40**: 137-206; Anderson WF (1998) *Nature* **392**: (6679 Suppl): 25-30.).

A further preferred vector is the adeno-associated (AAV) vector. AAV vectors are well known to those skilled in the art and have been used to stably transduce human T-lymphocytes, fibroblasts, nasal polyp, skeletal muscle, brain, erythroid and haematopoietic stem cells for gene therapy applications (Phillip *et al* (1994). *Mol Cell Biol* **14**: 2411-2418; Russell *et al* (1994) *Proc Natl Acad Sci USA* **91**: 8915-8919; Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB and Carter BJ (1993). *Proc Natl Acad Sci USA* **90**: 10613-10617; Walsh *et al* (1994). *Proc Natl Acad Sci USA* **89**: 7257-7261; Miller *et al* (1994) *Proc Natl Acad Sci USA* **91**: 10183-10187; Emerson (1996). *Blood* **87**, 3082-3088). International Patent Application WO 91/18088 describes specific AAV based vectors.

Preferred episomal vectors include transient non-replicating episomal vectors and self-replicating episomal vectors with functions derived from viral origins of replication such as those from EBV, human papovavirus (BK) and BPV-1. Such integrating and episomal vectors are well known to those skilled in the art and are fully described in the body of literature well known to those skilled in the art. In particular, suitable episomal vectors are described in WO98/07876.

Mammalian artificial chromosomes can also be used as vectors in the present invention. The use of mammalian artificial chromosomes is discussed by Calos (1996 *Trends In Genetics* **12**: 463-466).

11/Dec/2002

8

In a preferred embodiment, the vector of the present invention is a plasmid. The plasmid may be is a non-replicating, non-integrating plasmid.

The term "plasmid" as used herein refers to any nucleic acid encoding an expressible gene and includes linear or circular nucleic acids and double or single stranded nucleic acids. The nucleic acid can be DNA or RNA and may comprise modified nucleotides or ribonucleotides, and may be chemically modified by such means as methylation or the inclusion of protecting groups or cap- or tail structures.

A non-replicating, non-integrating plasmid is a nucleic acid which when transfected into a host cell does not replicate and does not specifically integrate into the host cell's genome (i.e. does not integrate at high frequencies and does not integrate at specific sites). As used herein, 'host cell' refers to any cell used the replicate a vector, or to express a product from such a vector. It does not imply any particular source of the cell.

Replicating plasmids can be identified using standard assays including the standard replication assay of Ustav *et al.* (1991 EMBO J 10: 449-457).

Numerous techniques are known and are useful according to the invention for delivering the vectors described herein to cells, including the use of nucleic acid condensing agents, electroporation, complexing with asbestos, polybrene, DEAE cellulose, Dextran, liposomes, cationic liposomes, lipopolyamines, polyornithine, particle bombardment and direct microinjection (reviewed by Kucherlapati and Skoultschi, 1984 CRC Crit. Rev. Biochem 16: 349-379; Keown *et al.*, 1990 Methods Enzymol 185: 527-37).

A vector of the invention may be delivered to a host cell non-specifically or specifically (i.e., to a designated subset of host cells) via a viral or non-viral means of delivery. Preferred delivery methods of viral origin include viral particle-producing packaging cell lines as transfection recipients for the vector of the present invention into which viral packaging signals have been engineered, such as those of adenovirus, herpes viruses and papovaviruses. Preferred non-viral based gene delivery means and methods may also be used in the invention and include direct naked nucleic acid injection, nucleic acid condensing peptides and non-peptides, cationic liposomes and encapsulation in liposomes.

11/Dec/2002

9

The direct delivery of vector into tissue has been described and some short-term gene expression has been achieved. Direct delivery of vector into muscle (Wolff *et al.*, 1990) thyroid (Sikes *et al.*, 1994 Human Gene Therapy 5: 837-844.) melanoma (Vile *et al.*, 1993 Vile RG and Hart IR (1993, Cancer Res 53: 962-967.), skin (Hengge *et al.*, 1995, Nature Genet 10: 161-166.), liver (Hickman *et al.*, 1994, Human Gene Therapy 5: 1477-1483.) and after exposure of airway epithelium (Meyer *et al.*, 1995, Gene Therapy, 2, 450-460, 1995) is clearly described in the prior art.

Various peptides derived from the amino acid sequences of viral envelope proteins have been used in gene transfer when co-administered with polylysine DNA complexes (Plank *et al.*, 1994, J Biol Chem 269: 12918-12924.; Trubetskoy *et al.*, 1992, Bioconjugate Chem 3: 323-327; WO 91/17773; WO 92/19287) and Mack *et al.*, (1994, Am J Med Sci 307: 138-143.) suggest that co-condensation of polylysine conjugates with cationic lipids can lead to improvement in gene transfer efficiency. International Patent Application WO 95/02698 discloses the use of viral components to attempt to increase the efficiency of cationic lipid gene transfer.

Nucleic acid condensing agents useful in the invention include spermine, spermine derivatives, histones, cationic peptides, cationic non-peptides such as polyethyleneimine (PEI) and polylysine. 'Spermine derivatives' refers to analogues and derivatives of spermine and include compounds as set forth in International Patent Application WO 93/18759 (published September 30, 1993).

Disulphide bonds have been used to link the peptidic components of a delivery vehicle (Cotten *et al.*, 1992, Enzymol 217: 618-644.); see also Trubetskoy *et al.* (*supra*).

Delivery vehicles for delivery of DNA constructs to cells are known in the art and include DNA/poly-cation complexes which are specific for a cell surface receptor, as described in, for example, Wu and Wu, 1988, J Biol Chem 263:14621; Wilson *et al.*, 1992, J Biol Chem 267: 963-967; and U.S. Patent No. 5,166,320.

Delivery of a vector according to the invention is contemplated using nucleic acid condensing peptides. Nucleic acid condensing peptides, which are particularly useful for condensing the vector and delivering the vector to a cell, are described in International Patent Application WO 96/41606. Functional groups may be bound to peptides useful for delivery of a vector

11/Dec/2002

10

according to the invention, as described in WO 96/41606. These functional groups may include a ligand that targets a specific cell-type such as a monoclonal antibody, insulin, transferrin, asialoglycoprotein, or a sugar. The ligand thus may target cells in a non-specific manner or in a specific manner that is restricted with respect to cell type.

The functional groups also may comprise a lipid, such as palmitoyl, oleyl, or stearoyl; a neutral hydrophilic polymer such as polyethylene glycol (PEG), or polyvinylpyrrolidone (PVP); a fusogenic peptide such as the HA peptide of influenza virus; or a recombinase or an integrase. The functional group also may comprise an intracellular trafficking protein such as a nuclear localisation sequence (NLS), an endosome escape signal such as a membrane disruptive peptide, or a signal directing a protein directly to the cytoplasm.

In a further aspect, the invention provides a host cell transfected or transduced with, or otherwise containing, the isolated polynucleotide or vector comprising such a polynucleotide of the present invention. Preferably it is an antigen presenting cell. More preferably, it is a dendritic cell and, most preferably, it is an autologous cell derived from the patient and transfected or transduced either *in vivo* or *ex vivo*.

Alternatively, the host cell may be loaded or pulsed so that it contains the protein of the invention, or an immunogenic peptide or epitope derived therefrom. As will be understood by those of skill in the art, in such circumstances antigen presentation by means of the MHC Class II mechanism is favoured, whilst with delivery of the antigen to the cell in the form of an expressible polynucleotide, presentation via the MHC Class I mechanism is favoured. In preferred embodiment, both approaches are used, with autologous dendritic cells both loaded with peptide antigen and transfected with expressible polynucleotide encoding the same or different peptides or antigens as part of an *ex vivo* procedure before being returned to the patient.

In a further aspect, the invention provides a vaccine composition comprising the protein, peptide, epitope, polynucleotide, vector or host cell as described above, together with a pharmaceutically acceptable excipient, carrier, buffer or adjuvant.

In one preferred embodiment, the vaccine composition is a protein vaccine composition comprising the protein, peptide or epitope of the invention, together with a pharmaceutically acceptable excipient, carrier, buffer or adjuvant. Alternatively, it is a DNA vaccine

11/Dec/2002

11

composition comprising the polynucleotide or vector of the invention, together with a pharmaceutically acceptable excipient, carrier, buffer or adjuvant.

Also provided is the use of the protein, peptide, epitope, polynucleotide, vector or host cell of the invention as described above, for the manufacture of a medicament for the immunotherapy of cancer. Preferably, such use is for the manufacture of a medicament for the treatment of a cancer derived from a tissue or organ selected from the list consisting of; liver, lung, bladder, pancreas, brain, stomach, cervix, prostate, colorectal or ovary, or is a melanoma, lymphoma or leukaemia.

In a final aspect, the invention provides a method of treating a cancer by immunotherapy, comprising administering to a patient a vaccine composition comprising a polycomb protein, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide encoding said protein, peptide or epitope.

Alternatively, the method comprises administering to a patient a vaccine composition comprising a polynucleotide encoding a polycomb protein, or an immunogenic peptide or epitope derived therefrom. Preferably, the polynucleotide is included in a vector. More preferably the vector is an integrating vector. Alternatively it is a non-integrating vector. In either case, it is preferred that the vector is a viral vector, as described above.

In a preferred embodiment of the method, the protein is selected from the list consisting of Enx/EZH2, EED, BMI-1, RING-1, HPH1, HPH2, HPC3 and CtBP. More preferably, it is Enx/EZH2 or BMI-1. Most preferably, it is BMI-1.

In another preferred embodiment, the method comprises administering to a patient a vaccine composition comprising a host cell containing a polycomb protein, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide or vector encoding said protein, peptide or epitope. Preferably the cell is a dendritic cell, more preferably an autologous dendritic cell.

It is preferred that the cancer to be treated is derived from a tissue or organ selected from the list consisting of; liver, lung, breast, stomach, cervix, prostate, bladder, pancreas, brain, colorectal or ovary, or is a melanoma, lymphoma or leukaemia.

11/Dec/2002

12

Detailed description of the invention

Description of the Figures

The invention will now be described with reference to the following figures.

Figure 1 shows an example of a serum sample from an HCC (hepatocellular carcinoma) patient reacting with different HCC-derived cDNA clones. Clones 45 and 56 represent clones carrying different portions of BMI-1.

Figure 2 shows ELIspot results examining whether there are T cell responses to predicted BMI-1 epitopes in PBMC preparations from hepatocellular carcinoma patients. The peptides are: a predicted A0201 peptide – 'TLQ' (TLQDIVYKL); the predicted B2702/05 peptides – 'VRY' (VRYLETSKY) and 'KRY' (KRYLRCPAA); an HLA-A02-restricted epitope from alpha-fetoprotein – 'GVA' (GVALQTMKQ); and a B7-restricted peptide from EBNA3a (negative control) – 'RPPI' (RPPIFIRRL); 'T only' is T cells only and 'PBL' is peripheral blood lymphocytes alone.

Figure 3 shows ELIspot results examining whether there are T cell responses to predicted BMI-1 epitopes in PBMC preparations from a normal volunteer and an hepatocellular carcinoma patient. PBMC were untreated or infected with the adenoviruses indicated (ADE3C, EBNA3c expressing adenovirus; ADBGAL, β -galactosidase expressing adenovirus, ADBMI, BMI-1 expressing adenovirus).

Figure 4 shows ELIspot results examining whether there are T cell responses to predicted EZH2 epitopes in PBMC preparations from normal volunteers. The peptides are the predicted A0201 peptides, YMC – YMCCSFLFNL; SQA – SQADALKYV or FRK – FRKAQIQGL an HLA-B27 restricted peptide from EBNA3c (negative control).

Figure 5 shows immunohistochemical staining of tumour sections for BMI-1. The sections shown are a) hepatocellular carcinoma, b) gastric cancer, c) breast cancer and d) prostate cancer.

11/Dec/2002

13

Example 1 Humoral responses to BMI-1

Method

The serological detection of antigens using a recombinant cDNA expression library derived from a hepatocellular carcinoma (HCC, purchased from Novagen and confirmed with our own 'in house' library) was performed using serum from HCC patients and normal healthy controls. The sera were preabsorbed against both *E.coli* lysate and a phage λ lysate and then used to probe filters carrying the cDNA library. Briefly, a culture of BL21 cells are grown overnight and resuspended in 10mM $MgSO_4$. 600ul of these cells are incubated with 3ul of the cDNA HCC library for 15 minutes and then mixed with NZY agarose and plated out onto NZY agar plates. These are incubated for 6-8 hours until plaques are visible and then overlaid with IPTG soaked Hybond-C filters. The plates are stored overnight at 4°C and incubated at 37°C for 4 hours the next day. The filters are removed from the plates, washed 3 times in TBS-T and then blocked for an hour in TBS-T 5% milk. They are then washed again before incubating with the absorbed serum (1 in 1000 dilution in TBS-T 5% milk) for 2.5 hours room temperature, followed by washing and then incubating with the second antibody 1 in 1000 (goat anti-human IgG alkaline phosphatase conjugate, Sigma) for 2 hours at room temperature. Filters are washed again and stained using the Biorad alkaline phosphatase kit for no more than 10 minutes. Once the filters have dried positive plaques are identified and picked from the plates, eluted, rescreened and cloned to monoclonality. The insert is screened to check it is not patient specific by screening with a number of different patient sera and with normal sera. Screening controls include second step antibody alone to exclude anti-immunoglobulin responses and screening alongside a negative clone. Positive clones are then excised and sequenced. The sequences are compared to known sequences using the BLAST nucleotide search on the NCBI database.

Results

Three sequences were identified as different cDNA clones of BMI-1 using this approach. All 9 HCC patients screened had strong antibody responses to at least one of the clones. Normal donors were also screened and 5 out of 6 had responses to BMI-1 but these were weaker than those observed in the HCC patients.

Example 2 Prediction of HLA-A2 epitopes in BMI-1 and ELISpot studies

Epitopes were predicted from the BMI-1 protein sequence using the BIMAS (Bioinformatics and Molecular Analysis Section) web site (Parker, KC *et al* 1994 Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163). The peptides were selected according to scores compared to known epitopes from Epstein-Barr virus.

A0201 peptides - TLQDIVYKL and CLPSPSTPV;

B2702/05 peptides - VRYLETSKY and KRYLRCPAA;

B4402/03 peptides - YEEEPLKDY and KEEVNDKRY.

Elispots were performed using these peptides on peripheral blood mononuclear cells (PBMCs) from HCC patients and normal donors. Frozen PBMC were recovered overnight before use and the assays were performed in duplicate where possible using $2-4 \times 10^5$ cells per well. Peptides were used at concentration of 100µg/ml adding 10µl per well. The final well volume was 100µl. The plates were incubated overnight and then washed, antibodies added and stained according to usual protocols. The plates were counted using an automated system (AID, Strassburg, Germany).

Results

Specific T cell responses (IFN γ secretion) can be seen to a single HLA-A02 restricted peptide in an HLA-A02 patient (Figure 2A), and in response to an HLA-B27 restricted peptide in a HLA-B27 patient (Figure 2B).

Example 3 ELISpot studies with AdBMI-1 transduced presenting cells

Elispots were performed using peripheral blood mononuclear cells (PBMCs) from an HCC patient and a normal donor. These assays were performed in duplicate where possible using $2-4 \times 10^5$ cells per well. A replication-defective adenovirus containing the BMI-1 gene was produced in 293 cells and titred. PBMC were left to recover overnight if frozen samples were used, and then used in the ELISpot. Adenovirus was added at a MOI of 100. The plates were incubated overnight and then washed, antibodies added and stained according to usual

11/Dec/2002

15

protocols. The plates were counted using an automated system (AID, Strassburg, Germany). See Figure 3.

Example 4 Generation of anti-BMI CTL *in vitro*

Experiments are underway to generate CD8+ BMI-1 specific T cells by reactivation *in vitro*. A variety of restimulation protocols may be being employed, including the use of autologous dendritic cells or Langerhans cells, either pulsed with peptide epitopes or infected with the recombinant adenovirus expressing the whole protein. A novel method of stimulation labels autologous B cells with a streptavidin-conjugated anti-CD20 antibody followed by a biotin-labelled monomeric HLA-A2/peptide complex.

Once successfully isolated, BMI-1 specific cytotoxic T lymphocytes are used to confirm that target cells endogenously processing the antigen are able to be efficiently recognised.

Example 5 Prediction of HLA-A2 epitopes in EZH2 and ELISpot studies

Epitopes were predicted for EZH2 using the same protocol as Example 2.

A0201 peptides - YMCSFLFNL and SQADALKYV.

B2702/05 peptides - KRFRRADEV and YRYSQADAL.

B4402/03 peptides EELFVDYRY and KESRPPRKF.

Elispots were carried out as described in Example 2.

See Figure 4.

Example 6 Generation of anti-BMI-1 immune responses in murine models

Mice are vaccinated against BMI-1. Methodologies for vaccination against an antigen are well known in the art and include, but are not limited to, the use of protein vaccines, peptide vaccines and genetic vaccines. Methodologies for genetic vaccination are well known to individuals skilled in the field and can include, but are not limited to, i) vaccination using BMI-1 encoding plasmid DNA (by needle injection using intradermal, subcutaneous or intramuscular routes), ii) gene gun delivery of BMI-1 encoding plasmid DNA (by the subcutaneous route), iii) by recombinant, BMI-1 encoding, viral vectors, an example of such a vector would be a

11/Dec/2002

18

first generation adenovirus encoding BMI-1, or iv) by a combination of the above approaches, for example the commonly used prime boost approach where the first administration, priming administration, is with naked DNA, and the subsequent boost is with a recombinant viral vector. Common immunisation protocols involve at least two administrations at least 6 days apart. Naked DNA administrations by a needle normally involve injection of 1-100µg DNA by the intramuscular route. Gene Gun administrations use 0.1-10µg of DNA delivered by the intradermal/subcutaneous route. When using a replication defective (E1/E3 deleted) adenovirus such as that described in Xiang *et al.* Virology (1996) 219:220-227, one can administer 1×10^7 to 1×10^{10} pfu by the intramuscular, oral, intranasal or subcutaneous route. Following the last administration mice are usually left at least 5 days prior to harvesting serum to measure humoral responses or the spleen or lymph nodes to measure cellular responses. Humoral responses can be detected using a number of standard procedures well known to those skilled in the art. These methods include immunoblotting, Western blotting, a BMI-1 specific ELISA and radioimmuno-precipitation. These procedures are well-known to those skilled in the art. The following Western blotting protocol can be used to detect anti-BMI-1 antibodies in murine sera. Mice immunised with bmi-1 were bled at various time points following the vaccination. For each sample, protein extracts from a cell line expressing high amounts of Bmi-1 protein (MCF-7) are run on NuPAGE Bis-Tris pre-cast gel (Invitrogen), and transferred to a PVDF membrane using the Xcell II Blot module (Invitrogen) according to manufacturer instructions (30V constant for 1h in NuPAGE transfer Buffer + 10% methanol). After 1h blocking with casein at RT, membranes are blocked to avoid non-specific binding of biotin/avidin. This blocking step is performed using the Vector Blocking kit by 10 min incubation at RT in Avidin D solution (2 drops of Avidin D from the kit in 10ml TBS) followed by a brief wash and 10 minutes incubation at RT in biotin solution (2 drops of Biotin from the kit in 10ml TBS). After blocking, membranes are stained using VECTASTAIN ABC-Amp kit (Vector) according to the manufacturer's instructions. Briefly, membranes are incubated for 30min with various dilutions of mouse serum in PBS and washed. For all washings, 3 incubations of 4 min in casein solution (Vector) are performed, and all incubations are done at RT. Membranes are then incubated for 30min with 10ml of biotinylated anti-mouse IgG (Vector) diluted at 1.5µg/ml in casein solution. After washing, membranes are incubated 10min with VECTASTAIN ABC-Amp Reagent diluted 1:500 in casein solution, washed, equilibrated by 5min incubation in 0.1M Tris buffer pH 9.5, and stained with the Chromogenic Substrate Development kit (Vector, cat No. AK-6401). For this staining, membranes are incubated in the staining solution (4 drops of each reagent from the kit in 10ml of 0.1M Tris buffer pH 9.5) for 5 to 30 min and washed with water. To detect the anti-BMI-1 antibodies by

11/Dec/2002

17

radio-immunoprecipitation following can be used. Labeled recombinant BMI-1 can be produced by *in vitro* transcription and translation (Promega, UK) with ^{35}S -methionine (Amersham, UK) from a plasmid encoding BMI-1 under the SP6 or T7 promoter. *In vitro* translated ^{35}S -BMI-1 (20,000 cpm) is incubated overnight at 4°C with 2 µl of diluted hyperimmune murine serum (1:25 to 1: 500). Autoantibody-bound antigen is precipitated with 25 µl of 25% protein A-Sepharose with 25% protein G-Sepharose (Amersham-Pharmacia, UK) in Multiscreen-DP opaque 96-well filtration plates (Millipore, UK) and is washed 8 times with washing buffer (20 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 0.1% BSA, and 0.15% Tween-20) using a Millipore vacuum-operated 96-well plate washer (Millipore, UK). After washing, scintillation fluid is added directly to the 96-well plate and radioactivity counted on a TopCount 96-well plate beta counter (Packard).

Cellular immune responses can be demonstrated by demonstrating T cell-derived antigen specific cytolytic activity or IFN γ secretion in response to BMI-1 presenting target cells. Spleens are removed from mice 10 days after the last BMI-1 immunisation. The spleen cells are immediately cocultured with syngenic Bone Marrow-derived Dendritic Cells (BMDC) transfected with a bmi-1 encoding construct using a non-viral transfection system, or electroporation. BMDC transfected with an irrelevant cDNA are used as negative controls, as well as spleen cells from mice immunised with irrelevant cDNA and adenovirus. Coculture is performed in ELISPOT plates (Millipore) coated with IFN- γ mAb with 5×10^5 splenocytes/well and up to 1×10^5 BMDC/well. After 24h co-culture in 200 µl of RPMI 10% FCS, ELISPOT plates are washed and stained according to manufacturer instructions and spots are counted using digital image analyser software. BMDC are generated by culturing mouse BM cells (flushed from femurs and tibia), depleted of T cells and erythrocytes (cocktail of anti-CD4, -CD8, -CD45R followed by lysis with guinea pig complement and red cell lysis buffer.), in 500U/ml murine GM-CSF and 1000U/ml murine IL-4.

Example 7 Anti-tumour responses in murine model(s)

Mice are vaccinated against BMI-1 using protocols and procedures as described in Example 6. The vaccinated mice are then challenged with a BMI-1 expressing syngeneic tumour cell line. The anti-tumour activity of the anti-BMI-1 immunisation is demonstrated by observed protection from challenge with the BMI-1 expressing tumour. An appropriate tumour model for this study is the murine mammary cell line 4T1 in Balb/c mice.

11/Dec/2002

18

Example 8 Immunostaining of primary tumour samples.**Method**

Embedded tissue sections were stained as follows: the sections were soaked in xylene for 5 mins, alcohol for 5 mins, returned to water, and then treated with 0.3% H₂O₂ in H₂O for 15 mins followed by a wash in water. The sections were placed in EDTA buffer pH8 plus Tween20 @ 65°C on a hotplate stirrer (500rpm) overnight (ALTER technique by GM Reynolds: Reynolds, G.M., Billingham, L.J., Gray, L.J., Flavell, J.R., Cocker, J., Scott, K., Young, L.S. and Murray, P.G. (2002) IL-6 expression in Hodgkin/Reed-Sternberg cells is associated with the presence of 'B' symptoms and failure to achieve complete remission in patients with advanced Hodgkin's disease. Br. J. Haematol. 118; 195-201). Slides were rinsed in water and were mounted onto a Sequenza™ (ThermoShandon, Runcorn, UK) and washed in TBS (Tris-buffered saline) pH 7.6. They were then incubated in primary anti-BMI-1 Ab (either a 1:10 dilution in TBS for 4 hrs for mC69 Ab (gift from Arie Otte, University of Amsterdam), or a 1:100 dilution in TBS for 1 hr for clone 229F6 mAb (Upstate Cell signalling Solutions, Milton Keynes, UK). Slides were then washed in TBS plus Tween20 and incubated in Dako EnVision™ secondary Ab (Dako UK Ltd, Ely, UK) for 30 mins. Slides were washed in TBS plus Tween20 and visualised by incubating in Vector NovaRED™ (Vector Laboratories, Peterborough, UK) for 10 mins. The slides were then counterstained in Mayers Haematoxylin for 10 secs, dehydrated, cleared and mounted.

Results

Figure 5 shows the over-expression of BMI-1 in a number of tumour specimens. In all sections the nuclei of tumour cells can be seen to clearly stain positive for the presence of BMI-1. Positive staining tumour cells are indicated by an arrow(s) on each of the slides.

11/Dec/2002

19

Claims

1. A polycomb protein, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide encoding said protein, peptide or epitope, for use as a medicament in the immunotherapy of cancer.
2. A polycomb protein, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide encoding said protein, peptide or epitope, according to claim 1, wherein the protein is selected from the list consisting of Enx/EZH2, EED, BMI-1, RING-1, HPH1, HPH2, HPC3 and CtBP.
3. BMI-1, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide encoding said protein, peptide or epitope, for use as a medicament in the immunotherapy of cancer.
4. Enx/EZH2, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide encoding said protein, peptide or epitope, for use as a medicament in the immunotherapy of cancer.
5. The protein, peptide, epitope or polynucleotide of any of claims 1 to 4, for use as a medicament for the treatment of a cancer selected from the list consisting of; liver, lung, breast, stomach, colorectal, cervix, prostate, bladder, pancreas, brain or ovary, or is a melanoma, lymphoma or leukaemia.
6. A vector comprising the polynucleotide of any of claims 1 to 5.
7. An integrating vector according to claim 6.
8. A non-integrating vector according to claim 6.
9. A viral vector according to either of claims 7 or 8.
10. A host cell comprising the polynucleotide of any of claims 1 to 5, or the vector of any of claims 6 to 9.
11. A host cell comprising the protein, peptide or epitope of any of claims 1 to 5.
12. The host cell of either of claims 10 or 11, wherein said cell is a dendritic cell.
13. A vaccine composition comprising the protein, peptide, epitope, polynucleotide, vector or host cell according to any of claims 1 to 12, together with a pharmaceutically acceptable excipient, carrier, buffer or adjuvant.
14. A protein vaccine composition comprising the protein, peptide or epitope according to any of claims 1 to 5, together with a pharmaceutically acceptable excipient, carrier, buffer or adjuvant.

11/Dec/2002

20

15. A DNA vaccine composition comprising the polynucleotide or vector according to any of claims 1 to 9, together with a pharmaceutically acceptable excipient, carrier, buffer or adjuvant.
16. Use of the protein, peptide, epitope, polynucleotide, vector or host cell according to any of claims 1 to 12, for the manufacture of a medicament for the immunotherapy of cancer.
17. Use according to claim 16, for the manufacture of a medicament for the treatment of a cancer derived from a tissue or organ selected from the list consisting of, liver, lung, breast, stomach, cervix, prostate, bladder, pancreas, brain, colorectal, ovary, or is a melanoma, lymphoma or leukaemia.
18. A method of treating a cancer by immunotherapy, comprising administering to a patient a vaccine composition comprising a polycomb protein, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide encoding said protein, peptide or epitope.
19. A method of treating a cancer by immunotherapy, comprising administering to a patient a vaccine composition comprising a polynucleotide encoding a polycomb protein, or an immunogenic peptide or epitope derived therefrom.
20. The method of claim 19 wherein the polynucleotide is included in a vector.
21. The method of claim 20 wherein the vector is an integrating vector.
22. The method of claim 20 wherein the vector is a non-integrating vector.
23. The method of either of claims 21 or 22 wherein the vector is a viral vector.
24. The method according to any of claims 18 to 23, wherein the protein is selected from the list consisting of Enx/EZH2, EED, BMI-1, RING-1, HPH1, HPH2, HPC3 and CtBP.
25. The method according to claim 24, wherein the protein is BMI-1.
26. A method of treating a cancer by immunotherapy, comprising administering to a patient a vaccine composition comprising a host cell containing a polycomb protein, or an immunogenic peptide or epitope derived therefrom, or an isolated polynucleotide or vector encoding said protein, peptide or epitope.
27. The method of claim 26 wherein said host cell is a dendritic cell.
28. The method of any of claims 18 to 27, wherein the cancer to be treated is derived from a tissue or organ selected from the list consisting of, liver, lung, breast, stomach, cervix, prostate, bladder, pancreas, brain, colorectal or ovary, or is a melanoma, lymphoma or leukaemia.

11/Dec/2002

21


Abstract**POLYCOMB PROTEINS.**

~~The invention relates to~~ ^Tthe use of polycomb group proteins as a tumour-associated antigens. Polycomb group proteins are highly involved in body architecture development, haematopoiesis and cell cycle control. Aberrant expression of polycomb proteins has been linked with haematological malignancies, mainly lymphomas. This invention relates to the use of these polycomb group proteins as antigens for cancer immunotherapy. Immunological responses can be raised against these proteins and such responses are active against polycomb protein overexpressing tumour cells. *The protein is preferably*

BMI-1 or Ezh/EZH2.



11/Dec/2002

22

Figure 1



11/Dec/2002

23

Figure 2**A****B**



11/Dec/2002

24

Figure 3**A****B**

11/Dec/2002

25


Figure 4**A****B**

11/Dec/2002

28


Figure 5

A



Positively staining
nuclei of
hepatocellular
carcinoma cells

B



Stromal cells show
significantly less
staining


Glandular
epithelial gastric
cancer cells
staining positive

11/Dec/2002

27


Figure 5

C



Breast cancer cells
staining highly
positive for BMI-1

D



Prostate cancer cells staining strongly for
BMI-1 compared to surrounding
poorly/negatively staining fibroblasts

PCT Application

GB0305403



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.